Absci, Twist Bioscience collaborate to design antibody using generative AI

Absci Corporation (ABSI) and Twist Bioscience Corporation (TWST) unveiled a collaboration to design a novel therapeutic using generative AI. Through this new collaboration, Absci and Twist will design a novel therapeutic candidate against an undisclosed target using Absci’s advanced generative AI platform and Twist’s synthetic DNA platform. The program will leverage Absci’s AI de novo design capabilities and Twist’s silicon-based synthesis platform, including its Multiplexed Gene Fragments for the testing and validation of antibody candidates designed using Absci’s generative AI technology platform. Twist and Absci intend to seek a partner for human clinical development and commercialization.